These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 29385987)

  • 1. An elevated expression of serum exosomal microRNA-191, - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker.
    Goto T; Fujiya M; Konishi H; Sasajima J; Fujibayashi S; Hayashi A; Utsumi T; Sato H; Iwama T; Ijiri M; Sakatani A; Tanaka K; Nomura Y; Ueno N; Kashima S; Moriichi K; Mizukami Y; Kohgo Y; Okumura T
    BMC Cancer; 2018 Jan; 18(1):116. PubMed ID: 29385987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma.
    Takahasi K; Iinuma H; Wada K; Minezaki S; Kawamura S; Kainuma M; Ikeda Y; Shibuya M; Miura F; Sano K
    J Hepatobiliary Pancreat Sci; 2018 Feb; 25(2):155-161. PubMed ID: 29130611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosome-encapsulated microRNA-4525, microRNA-451a and microRNA-21 in portal vein blood is a high-sensitive liquid biomarker for the selection of high-risk pancreatic ductal adenocarcinoma patients.
    Kawamura S; Iinuma H; Wada K; Takahashi K; Minezaki S; Kainuma M; Shibuya M; Miura F; Sano K
    J Hepatobiliary Pancreat Sci; 2019 Feb; 26(2):63-72. PubMed ID: 30561106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
    Akamatsu M; Makino N; Ikeda Y; Matsuda A; Ito M; Kakizaki Y; Saito Y; Ishizawa T; Kobayashi T; Furukawa T; Ueno Y
    PLoS One; 2016; 11(7):e0158669. PubMed ID: 27380024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma.
    Komatsu S; Ichikawa D; Miyamae M; Kawaguchi T; Morimura R; Hirajima S; Okajima W; Ohashi T; Imamura T; Konishi H; Shiozaki A; Ikoma H; Okamoto K; Taniguchi H; Otsuji E
    Expert Opin Biol Ther; 2015 Jun; 15(6):773-85. PubMed ID: 25819175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression.
    Roch AM; Ceppa EP; Al-Haddad MA; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Ann Surg; 2014 Oct; 260(4):680-8; discussion 688-90. PubMed ID: 25203885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated expression level of microRNA-196a is predictive of intestinal-type intraductal papillary mucinous neoplasm of the pancreas.
    Aso T; Ohtsuka T; Tamura K; Ideno N; Kono H; Nagayoshi Y; Ohuchida K; Ueda J; Takahata S; Shindo K; Aishima S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2014 Apr; 43(3):361-6. PubMed ID: 24622064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes.
    Lahat G; Lubezky N; Loewenstein S; Nizri E; Gan S; Pasmanik-Chor M; Hayman L; Barazowsky E; Ben-Haim M; Klausner JM
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S750-7. PubMed ID: 25069861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated expression of exosomal microRNA-21 as a potential biomarker for the early diagnosis of pancreatic cancer using a tethered cationic lipoplex nanoparticle biochip.
    Pu X; Ding G; Wu M; Zhou S; Jia S; Cao L
    Oncol Lett; 2020 Mar; 19(3):2062-2070. PubMed ID: 32194703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.
    Tulla KA; Maker AV
    Langenbecks Arch Surg; 2018 Mar; 403(2):151-194. PubMed ID: 29218397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
    Vila-Navarro E; Duran-Sanchon S; Vila-Casadesús M; Moreira L; Ginès À; Cuatrecasas M; Lozano JJ; Bujanda L; Castells A; Gironella M
    Clin Transl Gastroenterol; 2019 Apr; 10(4):e00029. PubMed ID: 31009404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.
    Abue M; Yokoyama M; Shibuya R; Tamai K; Yamaguchi K; Sato I; Tanaka N; Hamada S; Shimosegawa T; Sugamura K; Satoh K
    Int J Oncol; 2015 Feb; 46(2):539-47. PubMed ID: 25384963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Blood-based Gene-expression Scoring System for Cancer Screening in Patients With Branch-duct Intraductal Papillary Mucinous Neoplasms.
    Suzuki R; Tamura H; Honma R; Konno N; Irie H; Takagi T; Sugimoto M; Asama H; Sato Y; Yoshinori O; Nakamura J; Takasumi M; Kato T; Hashimoto M; Hikichi T; Imai JI; Watanabe S; Ohira H
    Anticancer Res; 2020 Nov; 40(11):6551-6561. PubMed ID: 33109597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Berger AW; Schwerdel D; Costa IG; Hackert T; Strobel O; Lam S; Barth TF; Schröppel B; Meining A; Büchler MW; Zenke M; Hermann PC; Seufferlein T; Kleger A
    Gastroenterology; 2016 Aug; 151(2):267-70. PubMed ID: 27343369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas.
    Lubezky N; Loewenstein S; Ben-Haim M; Brazowski E; Marmor S; Pasmanik-Chor M; Oron-Karni V; Rechavi G; Klausner JM; Lahat G
    Surgery; 2013 May; 153(5):663-72. PubMed ID: 23305591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
    Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
    Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
    Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
    J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-10a in Pancreatic Juice as a Biomarker for Invasive Intraductal Papillary Mucinous Neoplasm by miRNA Sequencing.
    Kuratomi N; Takano S; Fukasawa M; Maekawa S; Kadokura M; Shindo H; Takahashi E; Hirose S; Fukasawa Y; Kawakami S; Hayakawa H; Takada H; Nakakuki N; Kato R; Yamaguchi T; Nakayama Y; Kawaida H; Kono H; Inoue T; Kondo T; Ichikawa D; Enomoto N
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intraductal papillary mucinous carcinoma.
    Imamura T; Komatsu S; Nishibeppu K; Kiuchi J; Ohashi T; Konishi H; Shiozaki A; Yamamoto Y; Moriumura R; Ikoma H; Ochiai T; Otsuji E
    BMC Cancer; 2024 Jul; 24(1):907. PubMed ID: 39069624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.